Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM)

L. Maffioli, L. Mascheroni, V. Mongioj, M. Gasparini, M. T. Baldini, E. Seregni, M. R. Castellani, N. Cascinelli, G. Buraggi

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Iodine-123-(S)-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl) methyl] benzamide ([ 123I]-(S)-IBZM) is a radiolabeled benzamide usually employed to study neuropsychiatric disorders, such as schizophrenia and Parkinson's disease. The ectodermic origin of melanocytes and the presence of melanin in the substantia nigra are the theoretic basis of the experimental use of this class of tracers for melanoma imaging. Methods: Eleven patients with proven metastatic melanoma entered the study. Whole-body and planar scintigrams were performed 2, 4 and 24 hr after intravenous injection of a mean tracer activity of 205 MBq. The dosimetric evaluation was performed by the Medical Internal Radiation Dose Committee method. Results: The [ 123I]- (S)-IBZM scans allowed the detection of all six cutaneous lesions, five of six superficial pathologic lymph nodes, four of five pulmonary and one of two hepatic metastases. The maximum tumor-to-background ratio was 2.6 in planar images. The hepatobiliary excretion of the tracer may limit detection of intra-abdominal lesions. Dosimetry is similar to data for nononcologic patients. Conclusion: Although it is unclear if the mechanism of radiopharmaceutical uptake in melanoma is due to binding to membrane receptors or due to interactions with intracellular structures, radiolabeled benzamide is a promising tracer to detect melanoma.

Original languageEnglish
Pages (from-to)1741-1747
Number of pages7
JournalJournal of Nuclear Medicine
Volume35
Issue number11
Publication statusPublished - 1994

Fingerprint

Iodine
Melanoma
Neoplasm Metastasis
Radiopharmaceuticals
Melanocytes
Melanins
Substantia Nigra
Intravenous Injections
Parkinson Disease
Limit of Detection
Schizophrenia
Lymph Nodes
Radiation
Lung
Skin
Membranes
benzamide
3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide
Liver
Neoplasms

Keywords

  • dopamine receptors
  • IBZM
  • melanoma
  • tumor imaging

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Maffioli, L., Mascheroni, L., Mongioj, V., Gasparini, M., Baldini, M. T., Seregni, E., ... Buraggi, G. (1994). Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM). Journal of Nuclear Medicine, 35(11), 1741-1747.

Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM). / Maffioli, L.; Mascheroni, L.; Mongioj, V.; Gasparini, M.; Baldini, M. T.; Seregni, E.; Castellani, M. R.; Cascinelli, N.; Buraggi, G.

In: Journal of Nuclear Medicine, Vol. 35, No. 11, 1994, p. 1741-1747.

Research output: Contribution to journalArticle

Maffioli, L, Mascheroni, L, Mongioj, V, Gasparini, M, Baldini, MT, Seregni, E, Castellani, MR, Cascinelli, N & Buraggi, G 1994, 'Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM)', Journal of Nuclear Medicine, vol. 35, no. 11, pp. 1741-1747.
Maffioli, L. ; Mascheroni, L. ; Mongioj, V. ; Gasparini, M. ; Baldini, M. T. ; Seregni, E. ; Castellani, M. R. ; Cascinelli, N. ; Buraggi, G. / Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM). In: Journal of Nuclear Medicine. 1994 ; Vol. 35, No. 11. pp. 1741-1747.
@article{4b3ba68d4a284d4eb0b008856aa3ac90,
title = "Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM)",
abstract = "Iodine-123-(S)-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl) methyl] benzamide ([ 123I]-(S)-IBZM) is a radiolabeled benzamide usually employed to study neuropsychiatric disorders, such as schizophrenia and Parkinson's disease. The ectodermic origin of melanocytes and the presence of melanin in the substantia nigra are the theoretic basis of the experimental use of this class of tracers for melanoma imaging. Methods: Eleven patients with proven metastatic melanoma entered the study. Whole-body and planar scintigrams were performed 2, 4 and 24 hr after intravenous injection of a mean tracer activity of 205 MBq. The dosimetric evaluation was performed by the Medical Internal Radiation Dose Committee method. Results: The [ 123I]- (S)-IBZM scans allowed the detection of all six cutaneous lesions, five of six superficial pathologic lymph nodes, four of five pulmonary and one of two hepatic metastases. The maximum tumor-to-background ratio was 2.6 in planar images. The hepatobiliary excretion of the tracer may limit detection of intra-abdominal lesions. Dosimetry is similar to data for nononcologic patients. Conclusion: Although it is unclear if the mechanism of radiopharmaceutical uptake in melanoma is due to binding to membrane receptors or due to interactions with intracellular structures, radiolabeled benzamide is a promising tracer to detect melanoma.",
keywords = "dopamine receptors, IBZM, melanoma, tumor imaging",
author = "L. Maffioli and L. Mascheroni and V. Mongioj and M. Gasparini and Baldini, {M. T.} and E. Seregni and Castellani, {M. R.} and N. Cascinelli and G. Buraggi",
year = "1994",
language = "English",
volume = "35",
pages = "1741--1747",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "11",

}

TY - JOUR

T1 - Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM)

AU - Maffioli, L.

AU - Mascheroni, L.

AU - Mongioj, V.

AU - Gasparini, M.

AU - Baldini, M. T.

AU - Seregni, E.

AU - Castellani, M. R.

AU - Cascinelli, N.

AU - Buraggi, G.

PY - 1994

Y1 - 1994

N2 - Iodine-123-(S)-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl) methyl] benzamide ([ 123I]-(S)-IBZM) is a radiolabeled benzamide usually employed to study neuropsychiatric disorders, such as schizophrenia and Parkinson's disease. The ectodermic origin of melanocytes and the presence of melanin in the substantia nigra are the theoretic basis of the experimental use of this class of tracers for melanoma imaging. Methods: Eleven patients with proven metastatic melanoma entered the study. Whole-body and planar scintigrams were performed 2, 4 and 24 hr after intravenous injection of a mean tracer activity of 205 MBq. The dosimetric evaluation was performed by the Medical Internal Radiation Dose Committee method. Results: The [ 123I]- (S)-IBZM scans allowed the detection of all six cutaneous lesions, five of six superficial pathologic lymph nodes, four of five pulmonary and one of two hepatic metastases. The maximum tumor-to-background ratio was 2.6 in planar images. The hepatobiliary excretion of the tracer may limit detection of intra-abdominal lesions. Dosimetry is similar to data for nononcologic patients. Conclusion: Although it is unclear if the mechanism of radiopharmaceutical uptake in melanoma is due to binding to membrane receptors or due to interactions with intracellular structures, radiolabeled benzamide is a promising tracer to detect melanoma.

AB - Iodine-123-(S)-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl) methyl] benzamide ([ 123I]-(S)-IBZM) is a radiolabeled benzamide usually employed to study neuropsychiatric disorders, such as schizophrenia and Parkinson's disease. The ectodermic origin of melanocytes and the presence of melanin in the substantia nigra are the theoretic basis of the experimental use of this class of tracers for melanoma imaging. Methods: Eleven patients with proven metastatic melanoma entered the study. Whole-body and planar scintigrams were performed 2, 4 and 24 hr after intravenous injection of a mean tracer activity of 205 MBq. The dosimetric evaluation was performed by the Medical Internal Radiation Dose Committee method. Results: The [ 123I]- (S)-IBZM scans allowed the detection of all six cutaneous lesions, five of six superficial pathologic lymph nodes, four of five pulmonary and one of two hepatic metastases. The maximum tumor-to-background ratio was 2.6 in planar images. The hepatobiliary excretion of the tracer may limit detection of intra-abdominal lesions. Dosimetry is similar to data for nononcologic patients. Conclusion: Although it is unclear if the mechanism of radiopharmaceutical uptake in melanoma is due to binding to membrane receptors or due to interactions with intracellular structures, radiolabeled benzamide is a promising tracer to detect melanoma.

KW - dopamine receptors

KW - IBZM

KW - melanoma

KW - tumor imaging

UR - http://www.scopus.com/inward/record.url?scp=0028152644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028152644&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 1741

EP - 1747

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 11

ER -